Platinum‐based compounds are widely used as chemotherapeutics for the treatment of a
variety of cancers. The anticancer activity of cisplatin and other platinum drugs is believed to …

Background: Customizing chemotherapy on the basis of chemosentitivity prediction may
improve outcome in advanced bladder cancer patients. Since DNA damaging agents are the …

Study objectives Proteins of the nucleotide excision repair pathway repair DNA damage.
The excision repair cross-complementing (ERCC) gene family reduces damage to DNA by …

DNA damage response, DNA repair and genomic instability have been under study for their
role in tumor initiation and progression for many years now. More recently, next-generation …

Purpose Candidate predictive biomarkers for irinotecan and oxaliplatin were assessed in
1,628 patients in Fluorouracil, Oxaliplatin, CPT-11: Use and Sequencing (FOCUS), a large …

Purpose: We prospectively evaluated the predictive value of therapy-induced reduction of
tumor glucose use for subsequent response and patient survival in patients with gastric …

Background Conventional cytotoxic chemotherapy (CCC) is the backbone of non-small-cell
lung cancer (NSCLC) treatment since decades and still represents a key element of the …

Platinum-based chemotherapeutics represent a mainstay of cancer therapy, but resistance
limits their curative potential. Through a kinome RNAi screen, we identified microtubule …

Background: Platinum-based doublets are the standard chemotherapy for advanced non-
small-cell lung cancer (NSCLC). Excision-repair cross-complementing 1 (ERCC1) …

The results of cisplatin-based chemotherapy seem to have reached a plateau, and empirical
approaches are targeting the inclusion of novel biological agents with different mechanisms …